Vedere Bio
Daniel Zimmer is Senior Director, Program Lead at Vedere Bio. Prior to joining Vedere, he was a Senior Principal Investigator at Cyclerion, where he led the soluble guanylate cyclase stimulator discovery program, developed and executed pharmacology strategy, and contributed to clinical development of the oral soluble guanylate cyclase stimulators praliciguat and olinciguat. Prior to Cyclerion, he was a Principal Investigator at Ironwood Pharmaceuticals where he led multiple discovery programs. He holds S.B. degrees in biology and chemistry from MIT and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.
This person is not in any offices
Vedere Bio
Vedere Bio II, Inc.® is a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death.